These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7543775)

  • 1. Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide nonnucleoside compounds.
    Fletcher RS; Arion D; Borkow G; Wainberg MA; Dmitrienko GI; Parniak MA
    Biochemistry; 1995 Aug; 34(32):10106-12. PubMed ID: 7543775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme.
    Fletcher RS; Syed K; Mithani S; Dmitrienko GI; Parniak MA
    Biochemistry; 1995 Apr; 34(13):4346-53. PubMed ID: 7535561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide.
    Buckheit RW; Kinjerski TL; Fliakas-Boltz V; Russell JD; Stup TL; Pallansch LA; Brouwer WG; Dao DC; Harrison WA; Schultz RJ
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2718-27. PubMed ID: 8593008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains.
    Balzarini J; Brouwer WG; Felauer EE; De Clercq E; Karlsson A
    Antiviral Res; 1995 Jun; 27(3):219-36. PubMed ID: 8540745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
    McMahon JB; Buckheit RW; Gulakowski RJ; Currens MJ; Vistica DT; Shoemaker RH; Stinson SF; Russell JD; Bader JP; Narayanan VL; Schultz RJ; Brouwer WG; Felauer EE; Boyd MR
    J Pharmacol Exp Ther; 1996 Jan; 276(1):298-305. PubMed ID: 8558446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives).
    Balzarini J; Pérez-Pérez MJ; Vélazquez S; San-Félix A; Camarasa MJ; De Clercq E; Karlsson A
    Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5470-4. PubMed ID: 7539917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives.
    Esnouf RM; Stuart DI; De Clercq E; Schwartz E; Balzarini J
    Biochem Biophys Res Commun; 1997 May; 234(2):458-64. PubMed ID: 9177293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
    Debyser Z; Vandamme AM; Pauwels R; Baba M; Desmyter J; De Clercq E
    J Biol Chem; 1992 Jun; 267(17):11769-76. PubMed ID: 1376311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of phosphorolysis catalyzed by HIV-1 reverse transcriptase is responsible for the synergy found in combinations of 3'-azido-3'-deoxythymidine with nonnucleoside inhibitors.
    Cruchaga C; Odriozola L; Andréola M; Tarrago-Litvak L; Martínez-Irujo JJ
    Biochemistry; 2005 Mar; 44(9):3535-46. PubMed ID: 15736963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates.
    Buckheit RW; Snow MJ; Fliakas-Boltz V; Kinjerski TL; Russell JD; Pallansch LA; Brouwer WG; Yang SS
    Antimicrob Agents Chemother; 1997 Apr; 41(4):831-7. PubMed ID: 9087499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-(human immunodeficiency virus) activity of polyoxotungstates and their inhibition of human immunodeficiency virus reverse transcriptase.
    Moore PS; Jones CJ; Mahmood N; Evans IG; Goff M; Cooper R; Hay AJ
    Biochem J; 1995 Apr; 307 ( Pt 1)(Pt 1):129-34. PubMed ID: 7536411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment).
    Joshi P; Prasad VR
    J Virol; 2002 Jul; 76(13):6545-57. PubMed ID: 12050367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor.
    Merluzzi VJ; Hargrave KD; Labadia M; Grozinger K; Skoog M; Wu JC; Shih CK; Eckner K; Hattox S; Adams J
    Science; 1990 Dec; 250(4986):1411-3. PubMed ID: 1701568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
    Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase.
    Barnard J; Borkow G; Parniak MA
    Biochemistry; 1997 Jun; 36(25):7786-92. PubMed ID: 9201921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The quinoline U-78036 is a potent inhibitor of HIV-1 reverse transcriptase.
    Althaus IW; Gonzales AJ; Chou JJ; Romero DL; Deibel MR; Chou KC; Kezdy FJ; Resnick L; Busso ME; So AG
    J Biol Chem; 1993 Jul; 268(20):14875-80. PubMed ID: 7686907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of reverse transcriptase of human immunodeficiency virus type 1 and chimeric enzymes of human immunodeficiency viruses types 1 and 2 by two novel non-nucleoside inhibitors.
    Rubinek T; McMahon JB; Hizi A
    FEBS Lett; 1994 Aug; 350(2-3):299-303. PubMed ID: 7520874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone.
    Borkow G; Fletcher RS; Barnard J; Arion D; Motakis D; Dmitrienko GI; Parniak MA
    Biochemistry; 1997 Mar; 36(11):3179-85. PubMed ID: 9115994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mode of inhibition of HIV-1 reverse transcriptase by polyacetylenetriol, a novel inhibitor of RNA- and DNA-directed DNA polymerases.
    Loya S; Rudi A; Kashman Y; Hizi A
    Biochem J; 2002 Mar; 362(Pt 3):685-92. PubMed ID: 11879196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase.
    Borkow G; Barnard J; Nguyen TM; Belmonte A; Wainberg MA; Parniak MA
    J Virol; 1997 Apr; 71(4):3023-30. PubMed ID: 9060662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.